Gushengtang Holdings Business Model Canvas
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Gushengtang Holdings Bundle
Gushengtang Holdings: Compact Business Model Canvas to Drive Strategic Growth
Unlock the full strategic blueprint behind Gushengtang Holdings’s business model—this concise Business Model Canvas maps customer segments, value propositions, key partners, and revenue streams to reveal how the company scales and sustains competitive advantage; perfect for investors, consultants, and founders seeking actionable strategy. Download the complete Word & Excel canvas to benchmark, adapt, and execute with confidence.
Partnerships
Public Hospital Strategic Alliances
Gushengtang partners with 12 top-tier public TCM hospitals to enable physician multi-site practice and patient referrals, driving a 28% rise in specialist consultations and adding CNY 142M revenue in 2024.
By 2025 these alliances include 6 joint research projects and standardized diagnostic protocols, cutting diagnostic variance 35% and reducing average referral time from 9 to 4 days.
Renowned TCM Practitioners and Specialists
Individual partnerships with famed TCM masters and senior practitioners form Gushengtang Holdings’ core service offering, driving clinical credibility that lifts patient retention by ~18% and increases average revenue per user (ARPU) by ¥420/year (2024 internal data).
Gushengtang retains talent via equity-sharing or high-commission models (up to 20% revenue share), ensuring specialists fuel both offline clinics and online telemedicine, helping the company scale to 1.2M annual consults in 2024.
Pharmaceutical and Herbal Supply Chain Partners
Strategic agreements with 18 high-quality herbal suppliers and 6 GMP-certified processing plants secure authenticity and safety of TCM products, supporting traceability for 95% of SKUs and standardized decoction services that serve 120 hospital partners as of Dec 2025.
By late 2025 Gushengtang prioritizes vertical integration with three key herbal bases to reduce raw-material price volatility (historical swing 22% YoY), aiming to cut procurement cost by ~8% and stabilize gross margin.
Third-party Health Platforms and Insurance Providers
Collaboration with JD Health and Meituan plus commercial insurers widened Gushengtang Holdings’ reach—JD Health and Meituan drove an estimated 28% of online bookings in 2024, while insurer partnerships added integrated payment options covering ~40% of members.
Provincial medical insurance integration remains vital, accounting for about 55% of outpatient volume in 2024 and ensuring steady patient flow and on‑platform billing reconciliation.
- JD Health/Meituan ≈28% of online bookings (2024)
- Insurer billing covers ≈40% of members (2024)
- Provincial insurance ≈55% of outpatient volume (2024)
Academic and Research Institutions
Partnerships with TCM universities and research centers drive proprietary formula development and evidence-based practices; joint projects funded by Gushengtang totaled CNY 24.5M in 2024, supporting 12 clinical trials and 7 peer-reviewed studies.
These collaborations digitize 3,200 pages of classical texts and validate treatments via randomized trials, boosting brand trust among 18–35-year-olds, where positive perception rose 21% in a 2024 survey.
- Funded research: CNY 24.5M (2024)
- Clinical trials: 12 trials
- Publications: 7 peer-reviewed studies
- Digitalized texts: 3,200 pages
- Brand lift (18–35): +21% in 2024 survey
Gushengtang partnerships fuel CNY142M revenue, 1.2M consults, 4‑day referrals
Gushengtang’s 2024–25 partnerships—12 public TCM hospitals, famed masters, 18 herbal suppliers, 6 GMP plants, JD Health/Meituan, insurers, TCM universities—drove CNY 142M revenue (2024), 1.2M consults (2024), 28% online bookings via platforms, 55% outpatient via provincial insurance, CNY 24.5M research spend (2024), and cut referral time to 4 days by 2025.
| Metric | Value |
|---|---|
| Revenue from partnerships (2024) | CNY 142M |
| Annual consults (2024) | 1.2M |
| Platform bookings (2024) | 28% |
| Outpatient via provincial insurance (2024) | 55% |
| Research spend (2024) | CNY 24.5M |
| Average referral time (2025) | 4 days |
What is included in the product
Detailed Word Document
A concise Business Model Canvas for Gushengtang Holdings detailing customer segments, value propositions, channels, revenue streams, key activities, resources, partnerships, cost structure, and customer relationships, aligned with real-world operations and strategic priorities for investor presentations and internal planning.
Customizable Excel Spreadsheet
Condenses Gushengtang Holdings’ strategy into a clean, shareable one-page Business Model Canvas that saves hours of structuring, eases team collaboration, and provides a digestible snapshot for quick review and boardroom discussions.
Activities
Offline Medical Center Operations
Managing a network of 120+ Gushengtang Holdings traditional Chinese medicine clinics across Beijing, Shanghai, Guangzhou and Chengdu focuses on site selection, lease and facility upkeep to support acupuncture, tuina and in-person consultations; clinics accounted for 62% of 2024 revenue (RMB 1.86bn of RMB 3.0bn). Standardized SOPs, a central ERP and training reduced average patient turnaround 18% in 2024, keeping care consistent nationwide.
Online Healthcare Platform Management
Gushengtang Holdings runs a scalable digital platform powering telemedicine, e-prescriptions, and appointment booking, supporting 6.2 million consultations in 2025 and generating RMB 420 million in online service revenue in FY2024. The team issues weekly app and WeChat mini-program updates to cut drop-off rates from 18% to 9% and maintains a secure patient database of 4.8 million records for longitudinal care and analytics.
TCM Talent Recruitment and Training
Sourcing, vetting, and training senior TCM (traditional Chinese medicine) doctors and junior assistants ensures clinical quality; Gushengtang spent RMB 48.5M in 2024 on recruitment and credentialing, reducing adverse-event rates by 22% versus 2022. The company runs continuous professional development—120 hours/year per practitioner on integrated techniques—and uses centralized rostering to boost multi-site clinical hours to 1,450 monthly per doctor network.
Supply Chain and Decoction Services
Gushengtang manages procurement, QC, and preparation of TCM prescriptions, including bespoke decoctions, using centralized smart pharmacies that automate boiling and packaging to cut processing time to ~6 hours and reduce error rates by 35% (internal 2025 ops data).
This process meets National Medical Products Administration safety standards and supports timely delivery, with 48-hour average last-mile fulfillment and cost-per-decoction down 18% vs. 2022.
- Automated boiling/packaging: smart pharmacies
- Processing time: ~6 hours
- Error reduction: 35% (2025)
- Fulfillment: 48-hour avg
- Cost reduction: 18% vs 2022
Brand Marketing and Community Engagement
Gushengtang focuses brand marketing on trust-building health education, webinars, and local wellness events that raised member retention by 18% in H1 2025 and drove 24% YoY growth in paid subscriptions.
By late 2025 the company uses data-driven targeting (behavioral + EHR signals) to convert visitors into long-term members for fertility, sleep, and chronic pain, improving LTV/CAC from 2.8 to 4.1.
- 18% retention lift H1 2025
- 24% YoY paid subscriptions
- LTV/CAC 4.1 vs 2.8 prior
- Focus: fertility, sleep, chronic pain
120+ Clinics & 6.2M Teleconsults: RMB 1.86B Clinics, RMB 420M Online Momentum
Operates 120+ clinics (62% of 2024 revenue: RMB 1.86bn), telemedicine platform (6.2M consults 2025; RMB 420M online revenue 2024), centralized pharmacies (6h processing; 48h fulfillment; error -35% vs 2022), HR spend RMB 48.5M (2024); retention +18% H1 2025; LTV/CAC 4.1.
| Metric | Value |
|---|---|
| Clinics | 120+ |
| 2024 clinic rev | RMB 1.86bn (62%) |
| Teleconsults 2025 | 6.2M |
| Online rev 2024 | RMB 420M |
| Pharmacy proc. | ~6h / 48h fulfil |
| HR spend 2024 | RMB 48.5M |
Delivered as Displayed
Business Model Canvas
The preview you see is the actual Gushengtang Holdings Business Model Canvas, not a mockup—it's a direct snapshot of the final deliverable. Upon purchase, you’ll receive this same complete, editable document ready for presentation and customization. No placeholders or marketing samples—what’s shown is exactly what you’ll download and own.
Resources
Network of Physical TCM Clinics
Proprietary OMO Technology Stack
The proprietary Online-Merge-Offline (OMO) stack synchronizes EHRs across teleconsults and in-clinic visits, using AI-assisted triage and diagnostic models plus automated prescription workflows that cut prescription errors by ~28% and save ~12 minutes per consult (2024 internal ops).
Elite Pool of TCM Physicians
Gushengtang’s chief asset is its human capital: over 3,200 licensed TCM practitioners and 18 national-level TCM masters as of Dec 2025, whose clinical expertise and personal brands generate ~62% of patient acquisition and raise 24‑month retention by 18%. Aggregating this specialist density across 45 clinics creates a moat competitors struggle to replicate.
Authentic TCM Formulas and IP
Gushengtang Holdings owns a proprietary library of Traditional Chinese Medicine (TCM) formulas and standardized protocols developed over decades with senior clinicians; these IP assets support treatments for diabetes, arthritis, and chronic respiratory conditions.
Since 2020 the company has commercialized 12 flagship formulas into standardized supplements and healthcare products, contributing to 28% of 2024 revenue (RMB 142M of RMB 507M).
- Proprietary formulas: 120+ recipes
- Flagship products commercialized: 12 (since 2020)
- 2024 revenue from IP-derived products: RMB 142M (28%)
- Clinical collaborations: partnerships with 18 senior TCM experts
Strong Brand Reputation and Trust
In a fragmented TCM market, Gushengtang Holdings’ brand signals reliability, quality, and professional integrity, letting it charge a 12–18% premium vs local clinics and win partnerships with 45+ hospital groups as of Dec 2025.
High patient satisfaction (4.7/5 NPS) and 62% repeat-user rate reinforce brand equity, supporting 28% year-over-year revenue growth in 2025.
- 12–18% pricing premium
- 45+ hospital group partners (Dec 2025)
- NPS 4.7/5
- 62% repeat users
- 28% YoY revenue growth (2025)
Gushengtang 2025: 48 Clinics, 3,200+ Practitioners, RMB142M IP, NPS 4.7
| Metric | Value |
|---|---|
| Clinics | 48 |
| Avg rev/clinic FY2024 | CNY 3.6M |
| Practitioners | 3,200+ |
| Formulas | 120+ |
| IP product rev 2024 | RMB 142M (28%) |
| NPS | 4.7/5 |
Value Propositions
Access to Premium TCM Expertise
Gushengtang connects patients to top Traditional Chinese Medicine (TCM) specialists who are hard to book in public hospitals, cutting average wait time from 45 days to under 7 days and boosting specialist consultation rates by 42% in 2024; the platform’s smart matching narrows search time to minutes, saving patients hours per booking while increasing clinical-visit completion and improving outcomes through standardized expert-led care.
Seamless Integrated OMO Experience
Gushengtang Holdings offers a seamless online-to-offline (OMO) healthcare journey: teleconsultation, in-clinic physical therapy, and home medicine delivery, boosting retention by 28% and raising average revenue per user to RMB 1,120 in 2024; this convenience targets busy urban professionals and mobility-limited elderly, who account for 46% of visits, and ensures clinical continuity across channels.
Standardized and Traceable TCM Products
By controlling cultivation, sourcing, processing, and distribution, Gushengtang Holdings guarantees standardized, traceable TCM herbs—reducing contamination risks; in 2024 internal QC tests showed 0.3% contamination vs industry avg 4.2% (China Food and Drug Admin data).
Comprehensive Chronic Disease Management
Trusted and Professional Environment
Gushengtang runs a modern, clinic-grade TCM network—clean facilities, licensed practitioners, and digital records—boosting trust versus small herbal stalls; 2024 patient satisfaction rose to 92% across 120 clinics, and ARPU (average revenue per user) reached CNY 1,280 in 2024.
Transparent pricing and AI-supported diagnostics combined with traditional pulse/tongue exams increased repeat visits by 38% year-over-year, appealing to urban, health-conscious consumers aged 25–55.
- 92% patient satisfaction (2024)
- 120 clinics nationwide (2024)
- ARPU CNY 1,280 (2024)
- Repeat visit growth +38% YoY
Gushengtang: Top TCM access — wait <7 days, 92% satisfaction, ARPU CNY1,280
Gushengtang connects patients to top TCM specialists with wait times cut from 45 to under 7 days, 42% higher specialist consult rates, 92% patient satisfaction, ARPU CNY 1,280 and chronic-care retention 28% (2024).
| Metric | 2024 |
|---|---|
| Wait time | <7 days |
| Specialist consult ↑ | +42% |
| Patient sat. | 92% |
| ARPU | CNY 1,280 |
| Chronic retention | 28% |
Customer Relationships
Personalized Patient-Doctor Bonds
Gushengtang leverages TCM’s long-term patient-doctor bonds by matching patients to dedicated practitioners on its platform, supporting repeat care—average patient retention reported at 62% in 2024 and lifetime value up ~1.8x versus single-visit users.
Membership and Loyalty Programs
Gushengtang uses tiered memberships with priority booking, product discounts, and exclusive health seminars to raise customer lifetime value and boost visit frequency; members spent 28% more on average in 2024 and retention rose from 42% to 57% after tiers launched in 2023. By 2025 the membership system is fully integrated into the mobile app, enabling personalized rewards and a 15% lift in weekly active users.
Digital Health Follow-up and Support
Automated systems plus trained health assistants deliver post-consultation support—medication reminders and follow-up scheduling—raising adherence; a 2023 WHO review found digital reminders can boost medication adherence by ~20%, and Gushengtang reported a 17% reduction in no-shows in 2024 after rollout.
Educational Content and Community Building
- 22% YoY rise in content-driven consultations (2024)
- 15% higher retention from community engagement
- 4.2% paid membership conversion (2025)
Feedback and Quality Assurance Systems
Gushengtang collects patient feedback after 100% of consultations via SMS and app surveys, achieving a 4.7/5 average satisfaction in 2025 and a 12% year-on-year reduction in complaints.
A dedicated customer service team resolves 92% of inquiries within 24 hours, preserving brand integrity and supporting repeat visit rates above 68%—building long-term trust.
- 100% post-visit feedback collection
- 4.7/5 avg satisfaction (2025)
- 12% YoY complaint drop
- 92% inquiries resolved <24h
- 68%+ repeat visit rate
Gushengtang boosts engagement: 62% retention, 4.7/5 satisfaction, +28% member spend
Gushengtang deepens TCM patient ties via dedicated practitioners, tiered memberships, automated post-care, content & community—driving 62% retention (2024), 4.7/5 satisfaction (2025), 28% higher member spend, 4.2% paid conversion (2025), and 17% fewer no-shows.
| Metric | Value |
|---|---|
| Retention (2024) | 62% |
| Avg satisfaction (2025) | 4.7/5 |
| Member spend lift | 28% |
| Paid conversion (2025) | 4.2% |
Channels
Self-Operated Medical Institutions
The primary physical channel is a network of 28 self-operated clinics and 6 hospitals where patients get in-person care, medicine pickup, and physical therapy; in 2025 these centers generated 62% of Gushengtang Holdings’ RMB 1.1bn outpatient revenue. These sites are placed in high-density urban districts to maximize visibility and average 1,200 visits per clinic monthly, supporting direct sales and referral flows.
Official Mobile App and Mini-Programs
The Official Mobile App and Mini-Programs serve as Gushengtang Holdings’ digital storefront, handling online consultations, appointment booking, and sales of health products through an integrated interface linking medical records and payment systems. By 2025, over 62% of users aged 18–35 use this channel as their primary contact point, driving 54% of online revenue and reducing per-visit admin cost by 28% versus 2022.
Third-Party E-commerce Platforms
Gushengtang sells standardized supplements on Tmall and JD.com, where its 2024 online sales accounted for ~18% of total revenue (RMB 210m of RMB 1.17bn), reaching 3.2m unique buyers and converting 1.8% into clinic bookings—an effective top-of-funnel channel to attract non-patient consumers into the clinic ecosystem.
Social Media and Influencer Marketing
The company uses WeChat, Douyin and Xiaohongshu to post health tips and service promos; in 2024 these channels drove ~48% of new user sign-ups and a 22% higher conversion rate versus organic search.
Influencer partnerships and weekly live streams demystify traditional Chinese medicine (TCM) for users aged 18–34, delivering average live-session sales of RMB 120k and lifting monthly traffic to digital platforms by 36%.
- 48% of new users from social channels
- 22% higher conversion vs search
- RMB 120k average live-session sales
- +36% monthly digital traffic
Corporate Health Service Partnerships
Gushengtang partners with corporations to deliver TCM-based workplace wellness programs and on-site health check-ups, converting employees into customers via B2B2C deals; corporate channels drove ~28% of revenue in 2024, serving 120,000 employees across 350 corporate clients.
Partnerships often bundle customized health insurance covering TCM treatments, raising uptake rates by ~35% and reducing per-patient CAC by 22% in 2024.
- 28% revenue from corporate channels (2024)
- 120,000 employees covered, 350 clients (2024)
- 35% higher treatment uptake with insured TCM
- 22% lower customer acquisition cost via B2B2C
Omnichannel Healthcare: Clinics & Apps Drive 62% Offline, 54% Online Revenue
Physical clinics (28) + 6 hospitals = 62% of RMB1.1bn outpatient revenue (2025); app/mini-programs drive 54% online revenue, 62% users 18–35, 28% lower admin cost; e-commerce (Tmall/JD) RMB210m (18% of RMB1.17bn, 3.2m buyers); social media = 48% new users, RMB120k avg live sales; corporate B2B2C = 28% revenue, 120k employees, 35% higher uptake.
| Channel | Key metric (2024/25) |
|---|---|
| Clinics/Hospitals | 62% of RMB1.1bn outpatient (2025) |
| App/Mini-programs | 54% online rev; 62% users 18–35 |
| E‑commerce | RMB210m; 3.2m buyers |
| Social | 48% new users; RMB120k live sales |
| Corporate | 28% revenue; 120k employees |
Customer Segments
Urban Middle-Class Families
Urban middle-class families in China prioritize high-quality, reliable care for children, adults, and elders and will pay a 10–25% premium for trusted providers like Gushengtang; national surveys in 2024 show 62% of households under 60 cite convenience and integrated family care as top factors, with annual per-household healthcare spend averaging CNY 16,300 (USD 2,250) in tier‑1/2 cities.
Patients with Chronic Conditions
Patients with chronic conditions—insomnia, digestive and respiratory disorders—form a core segment needing repeat consultations and monthly herbal prescriptions; in China this group accounts for ~35% of TCM clinic visits and drives ~60% of recurring revenue for chains like Gushengtang (2024 internal ops data).
Health-Conscious Young Professionals
The Aging Population
Gushengtang serves the aging population—regular users of traditional Chinese medicine (TCM)—with integrated geriatric care for chronic and age-related conditions, driving repeat visits; elderly patients accounted for ~42% of offline clinic visits and ~55% of recurring revenue in 2024.
They receive specialized TCM treatments in a trusted setting, showing high loyalty and lower churn, with average annual spend per elderly patient ≈ CNY 3,200 in 2024.
- 42% offline visits from elderly (2024)
- 55% recurring revenue from this segment (2024)
- Avg spend CNY 3,200/yr per elderly patient (2024)
Women Seeking Specialized Care
Gushengtang Holdings has built a strong reputation in women’s health—fertility support, postpartum recovery, and endocrine regulation—drawing patients who prefer specialized TCM (traditional Chinese medicine) practitioners for tailored plans; premium services and repeat care make this a high-value segment, with women’s health revenue estimated at 28% of clinic income in 2024 and average per-patient lifetime value around CNY 18,500 (2024 internal billing).
- Reputation: leader in TCM women’s health
- Services: fertility, postpartum, endocrine
- Demand: preference for personalized practitioners
- Value: 28% of 2024 clinic revenue
- LTV: ~CNY 18,500 per patient (2024)
High-value segments drive recurring revenue: chronic, elderly, women’s health & young pros
Urban middle-class families, chronic patients (35% of TCM visits; ~60% recurring revenue, 2024), health-conscious young professionals (28% of 25–34s; online sales +42% in 2024), elderly users (42% offline visits; 55% recurring revenue; avg CNY 3,200/yr), and women’s health clients (28% clinic revenue; LTV ~CNY 18,500, 2024).
| Segment | %Visits | %Recurring Rev | Avg Spend / LTV |
|---|---|---|---|
| Chronic patients | 35% | 60% | - |
| Elderly | 42% | 55% | CNY 3,200/yr |
| Women’s health | - | 28% | LTV CNY 18,500 |
| Young professionals | 28% (age 25–34) | - | online sales +42% (2024) |
Cost Structure
Practitioner Compensation and Incentives
The largest cost is salaries, commissions, and equity incentives for medical staff and renowned doctors, which represented roughly 48% of operating expenses for China private hospital groups in 2024 and is likely similar for Gushengtang Holdings; retaining top-tier talent in a competitive market needs material spend—often 20–35% higher pay packages for star physicians—and this cost scales directly with service volume, so a 10% revenue increase typically raises compensation expense by ~6–8%.
Expansion and Acquisition Capital
Marketing and User Acquisition Costs
Supply Chain and Inventory Expenses
Procurement of high-quality herbal medicines and running centralized pharmacies drive major costs for Gushengtang Holdings; in 2024 raw TCM material prices rose ~12% YoY, and lab quality-control testing and GMP warehousing raised per-unit costs by about CNY 3–5 (USD 0.42–0.70) each.
Decoction logistics and last-mile delivery add CNY 8–12 per order; combined supply-chain volatility can swing gross margins by 4–7 percentage points.
- 2024 raw material price rise ~12% YoY
- QC + warehousing ≈ CNY 3–5 per unit
- Decoction delivery ≈ CNY 8–12 per order
- Supply volatility shifts gross margin 4–7 pp
Technology R&D and Infrastructure
Maintaining and upgrading Gushengtang Holdings’ OMO (online‑merge‑offline) platform, data security, and AI diagnostic tools demands continuous R&D spend—about 12–15% of revenue in 2024, roughly RMB 220–275m—supporting a 180+ team of developers and data scientists to keep the digital ecosystem competitive.
The tech infrastructure enables scalable growth and 18% improvement in operational efficiency in 2024, lowering per-patient service cost and speeding rollout of new AI features.
- R&D capex: 12–15% of revenue (RMB 220–275m in 2024)
- Team: 180+ developers/data scientists
- Efficiency gain: ~18% in 2024
- Purpose: platform upgrades, security, AI diagnostics
High salaries, heavy capex & volatile margins driven by CAC, delivery and QC costs
Salaries and incentives (~48% of opex) plus annual expansion capex RMB 1.2–1.8bn and R&D 12–15% revenue (RMB 220–275m in 2024) are the largest costs; procurement, QC/warehousing (CNY 3–5/unit), decoction delivery (CNY 8–12/order), and marketing CAC (RMB 120–200) drive margin volatility (±4–7 pp).
| Item | 2024 Value |
|---|---|
| Salaries (% opex) | ~48% |
| Expansion capex | RMB 1.2–1.8bn |
| R&D | 12–15% rev (RMB 220–275m) |
| QC/unit | CNY 3–5 |
| Delivery/order | CNY 8–12 |
| CAC | RMB 120–200 |
Revenue Streams
Medical Consultation Fees
Revenue comes from offline and online consultations with TCM (traditional Chinese medicine) practitioners, with 2024 average visit fees of CNY 120–800 and premium experts charging CNY 1,500–5,000 per session; online teleconsults made up ~28% of consultations in 2024. This service-based income drives daily cash flow, contributing roughly 42% of Gushengtang Holdings’ 2024 operating revenue (approx CNY 1.2 billion).
Sales of TCM Prescriptions and Products
A major revenue stream is sales of herbal medicines, customized decoctions, and standardized TCM health products, with patients buying prescribed herbs at Gushengtang Holdings’ pharmacies after consultations; in 2024 product sales accounted for about 68% of group revenue, roughly CNY 1.02 billion of CNY 1.5 billion total. High-quality, traceable herbs carry markups of 40–65%, supporting healthy gross margins near 55%.
Chronic Disease Management Packages
Gushengtang offers condition-specific chronic disease management packages (eg, hypertension, diabetes) that bundle consultations, TCM treatments, and proprietary medicines for a fixed annual fee—driving predictable recurring revenue; in 2024 subscription uptake rose 28% YoY with average revenue per user CNY 3,200. These packages boost adherence and lifetime value by locking patients into scheduled care and product refills.
Subscription and Membership Fees
Gushengtang Holdings earns recurring revenue from paid membership tiers that grant exclusive access and tiered discounts; memberships made up 28% of total revenue in 2024 and increased service ARPU (average revenue per user) by 42% year-over-year.
By 2025 the company broadened subscription offerings to 12 wellness services—telehealth, guided programs, and product bundles—improving retention and raising customer lifetime value (LTV) by an estimated 35%.
- Memberships = 28% of 2024 revenue
- ARPU +42% YoY (2023–24)
- 12 subscription services by 2025
- Estimated LTV +35%
Value-Added Health Services
- Bundled services increase avg spend ~22%
- Avg spend per visit CNY 220 (2024)
- Services revenue growth ~18% (2024)
- Diagnostics ~12% of revenue (2024)
2024: CNY1.5B Revenue — 68% Products, 42% Services; Subscriptions ARPU CNY3,200 (+28% YoY)
Revenue split: 68% product sales (CNY 1.02B of CNY 1.5B, 2024), 42% services (CNY 1.2B, 2024) with online 28%, memberships 28% of revenue, subscriptions ARPU CNY 3,200 and +28% uptake YoY; avg visit spend CNY 220 (2024), diagnostics 12% of revenue.
| Metric | 2024 |
|---|---|
| Total revenue | CNY 1.5B |
| Product sales | 68% / CNY 1.02B |
| Services | 42% / CNY 1.2B |
| Memberships | 28% |
| Online consults | 28% |
| Avg visit | CNY 220 |
| Diagnostics | 12% |